Chronic thromboembolic pulmonary hypertension after pulmonary embolism
Official title: Predictors for Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism Episode
Run by Assiut University · NCT06081881 · Data updated 2026-11-12
This project tests how often people who had an acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension (CTEPH) and which symptoms and echocardiography findings predict it in symptomatic patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Asyut) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | October 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | December 1, 2025 |
| Trial ID | NCT06081881 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with a recent acute pulmonary embolism and higher risk by PESI class III–V or sPESI ≥1 who have persistent symptoms are the intended participants.
✕Probably not a fit
Patients with known secondary causes of pulmonary hypertension, severe kidney or liver impairment, or contraindications to anticoagulation are unlikely to benefit or be eligible for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort of adults with recent acute pulmonary embolism who meet higher-risk PESI/sPESI criteria, followed to detect incident CTEPH. Participants undergo baseline clinical evaluation and transthoracic Doppler echocardiography with attention to RV function and specific Doppler signs, and are followed for imaging or clinical confirmation of CTEPH. Patients with secondary causes of pulmonary hypertension, severe renal or hepatic impairment, or contraindications to anticoagulation are excluded. The primary goal is to predict CTEPH occurrence in symptomatic post-PE patients using clinical and echocardiographic markers.
Why it matters
Potential benefit: If successful, earlier identification of patients at risk for CTEPH could enable timely referral for potentially curative treatments and reduce long-term disability.
How similar studies have gone: Previous observational cohorts have estimated CTEPH incidence after PE and identified echocardiographic and clinical risk factors, so this approach builds on existing, but still limited, evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1, Exclusion Criteria: Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation
Where it's running
-
Assiut University
Asyut, Egypt Recruiting
Study contacts
- Principal investigator: Ester A Faried, Resident — Assiut University
- Study coordinator: Ester A Faried, resident
- Email: esterashraf1810@gmail.com
- Phone: 01277194352
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up
This registry follows adults with acute pulmonary embolism to see how care is given in the real world and what happens over time.
-
Nailfold Capillaroscopy in Pulmonary Hypertension
This study tests whether nailfold capillary scans correlate with invasive lung blood pressure measurements and whether these patterns change with PH treatment.
-
How pulmonary endarterectomy affects confidence in managing chronic thromboembolic pulmonary hypertension
This project will see if pulmonary endarterectomy helps people with chronic thromboembolic pulmonary hypertension feel more confident managing their condition.
-
Registry of people with chronic thromboembolic pulmonary hypertension in Russia
This registry collects health, history, and treatment information from people in Russia with chronic thromboembolic pulmonary hypertension to see which factors relate to their prognosis.
-
Effects of stopping riociguat on heart function in patients with CTEPH
This study is testing how stopping the medication riociguat affects heart function in patients with inoperable CTEPH who have had balloon pulmonary angioplasty.
-
Switching from Sildenafil to Riociguat for CTEPH Patients
This study is testing if switching from sildenafil to riociguat can help people with Chronic Thromboembolic Pulmonary Hypertension feel better after they’ve already had balloon pulmonary angioplasty.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.